GlassScriptPhysician profile
Trina M Settles
NPI 1104834712
$1,179.19
in general payments reported to CMS, 2019-2025
27 companies · $97.04 in 2025
The $97.04 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.41 · 2020: $27.74 · 2021: $182 · 2022: $289 · 2023: $298 · 2024: $228 · 2025: $97.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $623.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.06 | 2021-2023 | Jardiance |
| Amgen INC. | $111.57 | 2020-2025 | Evenity, Prolia, Prolia |
| Lilly USA, LLC | $93.56 | 2022-2024 | Mounjaro, Jardiance |
| Pfizer INC. | $90.07 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.64 | 2022-2023 | Xifaxan, Trulance |
| Novo Nordisk INC | $66.71 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Medtronic, INC. | $66.09 | 2022-2023 | Minimed 780g |
| Astellas Pharma US INC | $54.43 | 2023 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $50.59 | 2019-2022 | |
| Mylan Specialty L.P. | $47.00 | 2021-2023 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $40.68 | 2023-2024 | Rexulti |
| Abbvie INC. | $39.10 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $37.40 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $36.88 | 2024-2025 | Voquezna |
| Abbott Laboratories | $36.60 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $28.87 | 2021-2022 | |
| Dexcom, INC. | $24.23 | 2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $19.84 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $19.27 | 2022 | |
| Insulet Corporation | $17.48 | 2025 | Omnipod |
| Janssen Pharmaceuticals, INC | $16.70 | 2021 | |
| Amarin Pharma, INC. | $16.70 | 2021 | |
| Sunovion Pharmaceuticals INC. | $14.24 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.85 | 2019 | |
| Esperion Therapeutics, INC. | $13.31 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.35 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trina Settles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.